Lung Cancer Patients Clinical Trials

3 recruiting

Lung Cancer Patients Trials at a Glance

6 actively recruiting trials for lung cancer patients are listed on ClinicalTrialsFinder across 6 cities in 5 countries. The largest study group is Not Applicable with 2 trials, with the heaviest enrollment activity in Boston, Fairfax, and Fuzhou. Lead sponsors running lung cancer patients studies include Fondazione Ricerca Traslazionale, Fujian Medical University Union Hospital, and Marc de Perrot.

Browse lung cancer patients trials by phase

Treatments under study

About Lung Cancer Patients Clinical Trials

Looking for clinical trials for Lung Cancer Patients? There are currently 3 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Lung Cancer Patients trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Lung Cancer Patients clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 16 of 6 trials

Recruiting
Not Applicable

Mindfulness-Oriented Respiratory Distress Symptom Intervention for Lung Cancer

Symptom ClusterBreathlessnessCoughing+3 more
The Hong Kong Polytechnic University64 enrolled1 locationNCT07281300
Recruiting
Phase 1

Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer

EGFR Mutation Positive Non-small Cell Lung CancerEGFR Mutated Non-small Cell Lung Cancer Patients
Nuvectis Pharma, Inc.18 enrolled3 locationsNCT07315113
Recruiting
Phase 2

Randomized Trial Comparing Standard of Care Versus Immune- Based Combination in Relapsed Stage III Non-small-cell Lung Cancer (NSCLC) Pretreated With Chemoradiotherapy and Durvalumab

Non-small-cell Lung Cancer Patients
Fondazione Ricerca Traslazionale176 enrolled1 locationNCT05568212
Recruiting
Not Applicable

Tubeless Anesthesia in Preventing Lung Complications in Patients Undergoing Surgery for Early-Stage Lung Cancer

Lung Cancer Patients
Fujian Medical University Union Hospital224 enrolled1 locationNCT07024433
Recruiting
Phase 2

Treatment of Pulmonary SUlcus, Pancoast and Chest Wall Non-small Cell Lung Cancer Employing Radiation, Immuno-oncology and Resection

Non-small Cell Lung Cancer (NSCLC)Lung Cancer Patients
Marc de Perrot12 enrolled1 locationNCT06331455
Recruiting

Inter-ethnic differences in tolerance of anti-cancer drugs in non-small cell lung cancer patients

tolerance of palliative chemotherapy with carboplatin and paclitaxel in advanced non-small cell lung cancer patients
Sydney Cancer Centre120 enrolled1 locationACTRN12611000013965